Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Cancerföräldraprogram för att förbättra livskvaliteten för patienter med avancerad cancer och deras barn (EC-PC)

25 augusti 2026 uppdaterad av: Frances M. Lewis, University of Washington

Enhancing Connections-Palliative Care: Ett cancerföräldraprogram för patienter med avancerad cancer och deras barn

This trial examines the usefulness of two educational programs for parents with late-stage cancer who have a 5 - 17 year old child. The programs are designed to enhance the quality of the parent-child relationship and add to the parent's confidence in managing the impact of their cancer on their child. Educational programs may reduce anxiety and depression and improve the well-being and quality of life of parents with advanced cancers and their children.

Recruitment occurs nationally via referral to the Fred Hutch/University of Washington Cancer Consortium team.

Studieöversikt

Detaljerad beskrivning

OUTLINE: Patients are randomized to 1 of 2 groups. Co-inhabiting non-ill parent or parent surrogate is also randomized with the patient but only the patient receives either the experimental or control group information.

GROUP I (ENHANCING CONNECTIONS-PALLIATIVE CARE [EC-PC] PROGRAM): Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child.

Group I had 2 arms: Arm 1: Ill parents Arm 2: Non-ill parents. The enrolled non-ill parent did not provide data to evaluate the efficacy of the trial.

GROUP II (CONTROL): Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.

Group II had 2 arms: Arm 1: Ill parents Arm 2: Non-ill parents. The enrolled non-ill parent did not provide data to evaluate the efficacy of the trial.

Studietyp

Interventionell

Inskrivning (Faktisk)

174

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • District of Columbia
      • Washington D.C., District of Columbia, Förenta staterna, 20007
        • Georgetown University
    • Washington
      • Seattle, Washington, Förenta staterna, 98115
        • Fred Hutch/University of Washington Cancer Consortium

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

23 år till 68 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Parents with any type of late-stage, non-curable cancer (determined by TNM stage IV cancer for solid tumors or 2 or more cycles of treatment failure with disease relapse in non-solid tumors)
  • All therapies are allowable
  • 23 years (yr.) to 68 yr. Age restriction exists for the patient based on parent having a child ages 5-17
  • Patient must have a child (5yr. -17 yr.) living in the home at least 50% of the time and residential with non-ill parent or parent surrogate
  • Read and write English as one of their languages of choice
  • Have access to a telephone
  • Ability to understand and the willingness to sign a written informed consent document. Read and write English as one of their languages of choice

Exclusion Criteria:

  • Patient is in hospice at time of enrollment
  • Non-ill co-parent does not consent to join study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Behavioral: Group 1: Educational counseling Group I (enhancing connections-palliative care program)

Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child.

Enrolled parents received 5 telephone-delivered educational counseling interventions at 2-week intervals, the EC-PC Program.

Andra namn:
  • EC-PC
Aktiv komparator: Group II (educational material)

Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.

Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.

Andra namn:
  • Kontrollgrupp

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Treatment Efficacy Assessed by Parents' Mood-Center for Epidemiological Studies-Depression (CES-D)
Tidsram: At 3 months post-baseline

Depressed mood will be measured by the 20-item Center for Epidemiological Studies- Depression Scale (CES-D) (Radloff, 1977). The CES-D Scale measures the recent occurrence of symptoms of depression. For each symptom, the respondent indicates the frequency with which that symptom has occurred during the past week, from "rarely or none of the time (less than 1 day)" to "most or all of the time (5-7 days)." This measure has been well- accepted in both ill and non-ill samples. Internal consistency in three samples from the general population has been reported by Radloff, 1977, and ranged between .84 to .85. Validity is well- established, including its link to the broader concept of "distress" in cancer-related research (Benazon & Coyne, 2000). The internal consistency reliability is 0.85 or higher (Benazon & Coyne, 2000). Total score ranges from 0-60. Higher scores denote worse outcome. Clinical cut off for distress is 16 or higher.

At 3 months post-baseline
Treatment Efficacy Assessed by Parents' Anxiety [Spielberger State-Trait Anxiety (STAI, State Scale)]
Tidsram: At 3 months post-baseline

State anxiety will be measured by the state component of the State-Trait Anxiety Inventory. This 20-item self-report questionnaire evaluates current feelings of apprehension, tension, nervousness, and worry. The respondent circles a response that best depicts their current feelings best. Response options range from [1 - Not at all] to [5 - Very much so]. Sample items include "I feel calm", I am tense." Higher scores denote greater anxiety. Internal consistency reliability is 0.90 or above in community and population samples [Edwards and Clarke, 2004]. Scale range: 20-80. Clinical cut off for distress is 40 or higher. Missing data imputation caused scores to be non-whole integers.

At 3 months post-baseline
Parent's Confidence in Being Able to Talk With Her Child About the Child's Cancer-related Concerns (CASE Help Child Subscale)
Tidsram: At 3 months post-baseline

Parenting Self-efficacy: Measured by the Help Child subscale of the parent-reported cancer Self-efficacy Scale (CASE). The Help Child subscale (9 items) measures the parent's confidence in being able to talk with her child about the child's cancer-related concerns; e.g., "I can assist my child to talk out his/her worries about my cancer." Structured response options range from "Not at all confident" (1) to "Very confident." The internal consistency reliability The internal consistency reliabilities in the EC seminal trial with parents with early stage cancer was 0.97. Higher scores denote better outcome. Range of scores: 0-90. There is no known clinical cutoff score on this measure.

At 3 months post-baseline
Parents' Skills in Helping Their Child Cope and Manage the Toll of the Parents' Cancer (Connecting and Coping Subscale)
Tidsram: At 3 months post-baseline

Parenting skills will be measured by the parent reported Parenting Skills Checklist: Connecting and Coping subscale developed by the study team and tested for reliability and validity in a 6-state randomized control trial (Lewis et al., 2015). The measure describes the observable interactional behaviors parents can use to assist their child disclose, discuss, and cope with the parent's cancer. The developmental-contextual model of parenting was the conceptual basis for the measure. An example item on the Connecting and Coping subscale includes, "I work with my child to help my child manage the child's stress related to my cancer." Range of subscale: 0-50. Higher scores reflect a better outcome. There is no clinical cut off score for parents' skills.

At 3 months post-baseline
Child-Behavioral Emotional Functioning: Anxious/Depressed Score on the Child Behavioral Checklist (CBCL)
Tidsram: At 3 months post-baseline

The child's behavioral-emotional adjustment will be measured by 3 subscales: the Anxious/Depressed scores, Internalizing Problems score, and Externalizing Problems scores, all part of the Child Behavior Checklist. See specific subscale scores, entered separately below. Response options for all subscales range from 0 to 2 from "Not True (as far as you know)" to "Somewhat or Sometimes True" to "Very True or Often True." Higher scores denote worse outcomes. Range of scores for Internalizing and Externalizing Problems is 34-100 and 50-100 for the Anxious/Depressed score. Internal consistency reliabilities were established as 0.90 for the Internalizing score and 0.94 for the Externalizing score. For the current study, the CBCL form for 6-18 year-olds and its computer software were used. The theoretical range of scores on the Anxious/Depressed score is 50-100. The theoretical range of the Internalizing and Externalizing problems subscales are both 34-100.

At 3 months post-baseline

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Condensed Memorial Symptom Assessment Scale (CMSAS) - Psychological Symptoms Subscale
Tidsram: At 3-months post-baseline

Self-report quantitative scale of patient's reported symptoms. BUT this was assessed as a potential covariate in the efficacy analysis and was used as such. It is not a primary nor a secondary outcome. Scores range from 0-4 with higher scores denoting greater psychological symptoms. There is no known clinical cut off score.

At 3-months post-baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Frances M Lewis, RN, MN, PhD, University of Washington

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

19 juli 2022

Primärt slutförande (Faktisk)

21 maj 2025

Avslutad studie (Faktisk)

15 augusti 2025

Studieregistreringsdatum

Först inskickad

19 juli 2022

Först inskickad som uppfyllde QC-kriterierna

25 juli 2022

Första postat (Faktisk)

28 juli 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • RG1122669
  • R01NR019987-01A1 (U.S.S. NIH-anslag/kontrakt)
  • STUDY00011221 (Annan identifierare: Fred Hutch/University of Washington Cancer Consortium)
  • NCI-2022-08714 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Secondary analysis of data will be permitted after a specific plan is submitted to the Principal Investigator and Co-Investigators approve.

Plan should make explicit the analysis sample, rationale for study, aims of secondary analysis, proposed data analysis to be used, timeline for completion of analysis, and agreement to cite the parent study with appropriate acknowledgment.

Tidsram för IPD-delning

Data will become available after filing FINAL Report to NINR, NIH and after the efficacy results and analysis of study aims are published.

Kriterier för IPD Sharing Access

Scientists prepared with a PhD or equivalent degree will be granted access for secondary analysis, after their specific proposed plan is submitted and reviewed by PI and Co-Invesigators.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera